Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Inclusion Criteria: * Documented diagnosis of relapsed/refractory multiple myeloma (MM) * Subjects must have measurable disease * Subjects must have received ≥3 prior MM lines of therapy * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate hematologic, renal, liver, pulmonary, and cardiac functions * Life expectancy of at least 3 months without treatment Exclusion Criteria: * Subjects with known active or history of central nervous system (CNS) or leptomeningeal involvement of myeloma or plasma cell leukemia * Current or history of thyroid disorder (including hyperthyroidism), except for subjects with hypothyroidism controlled on a stable dose of hormone replacement therapy * Autologous stem cell transplantation within last 6 weeks prior to the start of lymphodepletion * Any prior allogeneic hematopoietic stem cell transplantation * Systemic anti-cancer therapy within 2 weeks prior to the start of lymphodepletion